Regulation of Different Inflammatory Diseases by Impacting the Mevalonate Pathway

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2009 Feb 5

PMID 19191903

Citations 18

Authors

Robert Zeiser

Kristina Maas

Sawsan Youssef

Christoph Durr

Lawrence Steinman

Robert S Negrin

Affiliations

Soon will be listed here.

Abstract

The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) interfere with the mevalonate pathway. While initially developed for their lipid-lowering properties, statins have been extensively investigated with respect to their impact on autoantigen and alloantigen driven immune responses. Mechanistically it was shown that statins modify immune responses on several levels, including effects on dendritic cells, endothelial cells, macrophages, B cells and T cells. Several lines of evidence suggest that statins act in a disease-specific manner and are not effective in each immune disorder. This review discusses possible modes of action of statins in modulating immunity towards autoantigens and alloantigens.

Citing Articles

Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities.

Askarizadeh F, Karav S, Jamialahmadi T, Sahebkar A Pharmacol Rep. 2024; 77(1):43-71.

PMID: 39680334 DOI: 10.1007/s43440-024-00678-2.

Excessive endometrial PlGF- Rac1 signalling underlies endometrial cell stiffness linked to pre-eclampsia.

Raja Xavier J, Rianna C, Hellwich E, Nikolou I, Lankapalli A, Brucker S Commun Biol. 2024; 7(1):530.

PMID: 38704457 PMC: 11069541. DOI: 10.1038/s42003-024-06220-7.

Lovastatin promotes the self-renewal of murine and primate spermatogonial stem cells.

Li C, Yao Z, Ma L, Song X, Wang W, Wan C Stem Cell Reports. 2023; 18(4):969-984.

PMID: 37044069 PMC: 10147841. DOI: 10.1016/j.stemcr.2023.02.011.

Repurposing Cardio-Metabolic Drugs to Fight Covid19.

Battistoni A, Volpe M High Blood Press Cardiovasc Prev. 2021; 28(5):419-423.

PMID: 34524680 PMC: 8441229. DOI: 10.1007/s40292-021-00475-5.

Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.

Shawki M, Elsayed N, Mantawy E, Said R Immunopharmacol Immunotoxicol. 2021; 43(4):395-409.

PMID: 34057871 PMC: 8171013. DOI: 10.1080/08923973.2021.1931302.

References

Langham R, Egan M, Dowling J, Gilbert R, Thomson N . Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation. 2001; 72(11):1826-9. DOI: 10.1097/00007890-200112150-00019. View

Ridker P, Rifai N, Pfeffer M, Sacks F, Moye L, Goldman S . Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998; 98(9):839-44. DOI: 10.1161/01.cir.98.9.839. View

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G . The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. 2007; 197(2):829-39. DOI: 10.1016/j.atherosclerosis.2007.07.031. View

Zhang X, Jin J, Peng X, Ramgolam V, Markovic-Plese S . Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008; 180(10):6988-96. DOI: 10.4049/jimmunol.180.10.6988. View

Raki M, Molberg O, Tollefsen S, Lundin K, Sollid L . The effects of atorvastatin on gluten-induced intestinal T cell responses in coeliac disease. Clin Exp Immunol. 2005; 142(2):333-40. PMC: 1809523. DOI: 10.1111/j.1365-2249.2005.02915.x. View

Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin R . Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007; 110(13):4588-98. PMC: 2234784. DOI: 10.1182/blood-2007-08-106005. View

Broz P, Ben-Haim N, Grzelakowski M, Marsch S, Meier W, Hunziker P . Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J Cardiovasc Pharmacol. 2008; 51(3):246-52. DOI: 10.1097/FJC.0b013e3181624aed. View

Eccles K, Sowden H, Porter K, Parkin S, Homer-Vanniasinkam S, Graham A . Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis. 2008; 200(1):69-79. DOI: 10.1016/j.atherosclerosis.2007.12.018. View

10.

Holschermann H, Hilgendorff A, Kemkes-Matthes B, Schonburg M, Bauer E, Tillmanns H . Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000; 69(9):1830-6. DOI: 10.1097/00007890-200005150-00017. View

11.

Stuve O, Youssef S, Weber M, Nessler S, von Budingen H, Hemmer B . Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest. 2006; 116(4):1037-44. PMC: 1401481. DOI: 10.1172/JCI25805. View

12.

Eto M, Kozai T, Cosentino F, Joch H, Luscher T . Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002; 105(15):1756-9. DOI: 10.1161/01.cir.0000015465.73933.3b. View

13.

Leung B, Sattar N, Crilly A, Prach M, McCarey D, Payne H . A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003; 170(3):1524-30. DOI: 10.4049/jimmunol.170.3.1524. View

14.

Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B . Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci. 2007; 28(7):342-9. DOI: 10.1016/j.tips.2007.05.001. View

15.

Kwak B, Mulhaupt F, Myit S, Mach F . Statins as a newly recognized type of immunomodulator. Nat Med. 2000; 6(12):1399-402. DOI: 10.1038/82219. View

16.

Ferreira G, Navarro T, Telles R, Andrade L, Sato E . Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford). 2007; 46(10):1560-5. DOI: 10.1093/rheumatology/kem186. View

17.

Weis M, Pehlivanli S, Meiser B, von Scheidt W . Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol. 2001; 38(3):814-8. DOI: 10.1016/s0735-1097(01)01430-9. View

18.

de Lemos J, Blazing M, Wiviott S, Lewis E, Fox K, White H . Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292(11):1307-16. DOI: 10.1001/jama.292.11.1307. View

19.

Atar S, Ye Y, Lin Y, Freeberg S, Nishi S, Rosanio S . Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2005; 290(5):H1960-8. DOI: 10.1152/ajpheart.01137.2005. View

20.

Davignon J . Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109(23 Suppl 1):III39-43. DOI: 10.1161/01.CIR.0000131517.20177.5a. View